Table 1. Profile of breast cancer patients (P1-P12).
| Patients | Stage | Age, years | ER | PR | HER2 | NK1-TR | DNA Sequencing for NK1-Tr |
|---|---|---|---|---|---|---|---|
| P1-P3 | IIIA | 36-73 | − | − | − | + | P1 |
| P4 | IIIA | 60 | + | + | + | + | P4 |
| P5-P8 | IIA | 38-82 | + | + | − | + | P6, P7 |
| P9 | I | 45 | + | + | − | + | P9 |
| P10 | I | 38 | + | + | + | + | |
| P11 | M0 | 45 | ND | ND | ND | + | |
| P12 | M0 | 40 | ND | ND | ND | + |
Cancer staging followed standard guidelines (43). β-PPT-A and substance P levels were studied with total RNA and cell extracts from surgical tissues (n = 12), as described (3). Mean β-PPT-A molecules per μg total RNA = 25 ± 7 (±SD). Substance P levels = 66 ± 11 pg/ml (±SD). Tissue extracts were prepared by homogenizing ≈0.2 g of tissues in 0.2 ml of PBS containing protease inhibitor cocktail. ER, estrogen receptor; PR, progesterone receptor; HER2, c-erbB-2; ND, not done.